The investigational drug rinatabart sesutecan (Rina-S) shrank tumors in 45.9% of patients with platinum-resistant ovarian ...

In a video interview with CURE, Dr. Elizabeth K. Lee explained that how a treatment affects daily life matters as much as how well it works.

An investigational antibody-drug conjugate demonstrated clinically meaningful and durable responses in patients with platinum-resistant ovarian cancer, including patients whose tumors had low or no ...

Stay full longer with these high-protein, high-fiber foods, from lentils and edamame to chia seeds and black beans, plus ...

Phase 1/2 RAINFOL-01 data show a 45.9% objective response rate and 12.1-month median duration of response, with antitumour activity observed regardless of FRα expression levels. Treatment with Rina-S ...

Rina-S delivered a 46% confirmed response rate and durable responses lasting 12 months in platinum-resistant ovarian cancer.

Genmab has reported data from Part C of the Phase I/II RAINFOL-01 trial of rinatabart sesutecan (Rina-S; GEN1184) in patients with platinum-resistant ovarian cancer.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Genmab’s rinatabart sesutecan (Rina-S) delivered durable responses in a Phase 2 trial in platinum-resistant ovarian cancer, providing encouraging validation for the centerpiece of its $1.8 billion ...

Genmab A/S ( GMAB) reported positive results from Part C of the Phase 1/2 RAINFOL-01 trial evaluating investigational antibody-drug conjugate rinatabart sesutecan (Rina-S) in patients with ...

Media Release COPENHAGEN, Denmark; Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) ...

Genmab A/S announced results from Part C of the Phase 1/2 RAINFOL-01 trial evaluating rinatabartsesutecan (Rina-S), an investigational folate receptor alpha (FRa)-targeted, topoisomerase I ...